Latest News from "The Pink Sheet" DAILY - GSK Doubles Up With Regulus

Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon

Watson's own citizen petitions blocking generics won't be an obstacle, company says.   read more

 

Bristol Hopes REMS Proposal Can Overcome Safety Concerns About Belatacept

FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.   read more

 

GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics

Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.   read more

 

Evidence-Based Medicine Should Drive Medical Liability Reform, Project HOPE's Wilensky Says

Providing protections to those who follow guidelines should appeal to both Republicans and Democrats, the former McCain campaign advisor says.   read more

 

Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs

In New Zealand the government is the primary funder of pharmaceuticals, with 21 District Health Boards holding the budget for both the community Pharmaceutical Schedule and hospital purchases.   read more

 

Reimbursement Risks Driving Contingency-Based Deals, GSK Exec Says

Industry executives address the rise of back-end loaded deals during the Bio Windhover Pharmaceutical Strategic Outlook conference Feb. 24.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here